Marked species differences in the bioavailability of midazolam in cynomolgus monkeys and humans

Xenobiotica

Volumn 36, Issue 4, 2006, Pages 331-340

  Sakuda, S ^a   Akabane, T ^a   Teramura, T ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Intestinal availability; Intestinal perfusion; Midazolam; Monkey; Species differences

Indexed keywords

ATENOLOL; MIDAZOLAM; MIDAZOLAM MALEATE; NADOLOL; PROPRANOLOL;

AREA UNDER THE CURVE; ARTICLE; CYNOMOLGUS MONKEY; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG METABOLISM; FIRST PASS EFFECT; FRACTION OF DOSE ABSORBED; HUMAN; INTESTINE; INTESTINE PERFUSION; LIVER; LIVER BLOOD FLOW; MALE; MEAN RESIDENCE TIME; MEASUREMENT; MONKEY; NONHUMAN; PERMEABILITY; PERMEABILITY COEFFICIENT; SPECIES DIFFERENCE;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, LIQUID; GABA MODULATORS; HUMANS; INTESTINES; LIVER; MACACA FASCICULARIS; MALE; MIDAZOLAM; MODELS, CHEMICAL; PERFUSION; SPECIES SPECIFICITY; TIME FACTORS;

MACACA FASCICULARIS;

EID: 33646818650     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250600571749     Document Type: Article

References (28)

1. Allonen H, Ziegler G, Klotz U. 1981. Midazolam kinetics. Clinical Pharmacology and Therapeutics 30:653-661.
2. Bjornsson TD, Callaghan JT, Einolf HJ, Fisher V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA. 2003. The conduct of in vitro and in vivo drug-drug interaction studies: A pharmaceutical research and manufactures of America (PhRMA) perspective. Drug Metabolism and Disposition 31:815-832.
3. Bohers H, Annaert P, Mannens G, Van Beijsterveldt L, Anciaux K, Verboven P, Meuldermans W, Lavrijsen K. 2001. Strategies for absorption screening in drug discovery and development. Current Topics in Medicinal Chemistry 1:367-383.
4. Chalasani N, Gorski JV, Patel NH, Hall SD, Galinsky RE. 2001. Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: Effects of transjugular intrahepatic portosystemic shunts. Hepatology 34:1103-1108.
5. Chiou WL, Buehler PW. 2002. Comparison of oral absorption and bioavailability of drugs between monkey and human. Pharmaceutical Research 19:868-874.
6. Dreyfuss J, Shaw JM, Ross JJ. 1978. Absorption of the β-adrenergic-blocking agent, nadolol, by mice, rats, hamsters, rabbits, dogs, monkeys and man: An unusual species difference. Xenobiotica 8:503-508.
7. Gorski JC, Hall SD, Jones DR, VandenBranden M, Wrighton SA. 1994. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochemical Pharmacology 47:1643-1653.
8. Hayes A, Cooper RG. 1971. Studies on the absorption, distribution and excretion of propranolol in rat, dog and monkey. Journal of Pharmacology and Experimental Therapeutics 176:302-311.
9. Heizmann P, Eckert M, Ziegler WH. 1983. Pharmacokinetics and bioavailability of midazolam in man. British Journal of Clinical Pharmacology 16(Suppl.):43S-49S.
10. 14C-midazolam in humans following oral dosing. Arzneimittel-Forshung 31:2220-2223.
11. Jacqz E, Billante C, Moysan F, Mathieu H. 1988. The non-human primate: A possible model for human genetically determined polymorphisms in oxidative drug metabolism. Molecular Pharmacology 34:215-217.
12. Kato M, Chiba K, Hisaka A, Ishigami M, Kayama M, Mizuno N, Nagata Y, Takakuwa S, Tsukamoto Y, Ueda K, Kusuhara H, Ito K, Sugiyama Y. 2003. The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein - quantitative analysis based on information from the literature. Drug Metabolism and Pharmacokinetics 18:365-372.
13. Komori M, Kikuchi O, Kitada M, Kamataki T. 1992a. Molecular cloning of monkey P450 1A1 cDNA and expression in yeast. Biochimica et Biophysica Acta 1131:23-29.
14. Komori M, Kikuchi O, Sakuma T, Funai J, Kitada M, Kamataki T. 1992b. Molecular cloning of monkey liver cytochrome P-450 cDNAs: Similarity of the primary sequences to human cytochromes P-450. Biochimica et Biophysica Acta 1171:141-146.
15. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. 1989. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Molecular Pharmacology 36:89-96.
16. Mandema JW, Tuk B, Van Steveninck AL, Breimer DD, Cohen AF, Danhof M. 1992. Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite α-hydroxymidazolam in healthy volunteers. Clinical Pharmacology and Therapeutics 51:715-728.
17. Mankowski DC, Laddison KJ, Christopherson PA, Ekins S, Tweedie DJ, Lawton MP. 1999. Molecular cloning, expression, and characterization of CYP2D17 from cynomolgus monkey liver. Archives of Biochemistry and Biophysics 372:189-196.
18. McKinnon RA, Burgess WM, Hall PM, Roberts-Thomson SJ, Gonzalez FJ, McManus ME. 1995. Characterisation of CYP3A gene subfamily expression in human gastrointestinal tissues. Gut 36:259-267.
19. Reeves PR, Barnfield DJ, Longshaw S, McIntosh DAD, Winrow MJ. 1978. Disposition and metabolism of atenolol in animals. Xenobiotica 8:305-311.
20. Rostami-Hodjegan A, Tucker GT. 2002. The effects of portal shunts on intestinal cytochrome P450 3A activity. Hepatology 35:1549-1551.
21. Rowland KY, Rostami-Hodjegan A, Tucker GT. 2004. Abundance of cytochromes P450 in human liver: A meta-analysis. British Journal of Clinical Pharmacology 57:687-688.
22. Salphati L, Childers K, Pan L, Tsutsui K, Takahashi L. 2001. Evaluation of a single-pass intestinal-perfusion method in rat for the prediction of absorption in man. Journal of Pharmacy and Pharmacology 53:1007-1013.
23. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. 1994. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics 270:414-423.
24. Smith MT, Eadie MJ, O'Rourke Brophy T. 1981. The pharmacokinetics of midazolam in man. European Journal of Clinical Pharmacology 19:271-278.
25. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, Wilkinson GR. 1996. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clinical Pharmacology and Therapeutics 59:491-502.
26. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Hartwell PS, Raisys VA, Marsh CL, McVicar JP, Barr DM, Perkins JD, Carithers RL. 1994. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. Journal of Pharmacology and Experimental Therapeutics 271:549-556.
27. Tsunoda SM, Velez RL, Von Moltke LL, Greenblatt DJ. 1999. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole. Clinical Pharmacology and Therapeutics 66:461-471.
28. Wrighton SA, Ring BJ. 1999. Predicting drug interactions and pharmacokinetic variability with in vitro methods: The olanzapine experience. Drug Metabolism Reviews 31:15-28.